Lenvatinib (brand name Lenvima) is an oral receptor tyrosine kinase (RTK) inhibitor used to treat specific types of advanced thyroid cancer, renal cell carcinoma (kidney cancer), and hepatocellular carcinoma (liver cancer). It works by blocking VEGFR1-3, FGFR1-4, PDGFR
, KIT, and RET, inhibiting angiogenesis and tumor growth. Common side effects include high blood pressure, fatigue, diarrhea, and proteinuria
Reviews
There are no reviews yet.